已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study

医学 淋巴血管侵犯 外科肿瘤学 危险系数 内科学 放化疗 食管鳞状细胞癌 倾向得分匹配 肿瘤科 腹部外科 食管癌 回顾性队列研究 比例危险模型 外科 胃肠病学 癌症 置信区间 转移
作者
Yoshinobu Yamamoto,Ryu Ishihara,Hirofumi Kawakubo,M. Nishikawa,Sachiko Yamamoto,Tomohiro Kadota,Seiichiro Abe,Masao Yoshida,Tsutomu Tanaka,Hiroaki Nagano,Hiroyoshi Nakanishi,Tetsuya Yoshizaki,Kotaro Waki,Akiko Takahashi,Yoshiyasu Kitagawa,Ken‐ichi Mizuno,Kenro Kawada,Yoshiyasu Kono,Chikatoshi Katada,Takashi Hashimoto,Yasuaki Nagami,Toshiyuki Yoshio,Toshio Shimokawa,Keiji Nihei,Kazuo Koyanagi,Ken Kato,Tomonori Yano,Manabu Muto,Yuko Kitagawa
出处
期刊:Journal of Gastroenterology [Springer Nature]
标识
DOI:10.1007/s00535-024-02188-7
摘要

Abstract Background Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered. Methods This was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence. Results Among 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group. Conclusions In patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Vicky完成签到 ,获得积分10
2秒前
还是你天天完成签到 ,获得积分10
2秒前
HMG1COA完成签到 ,获得积分10
3秒前
Akim应助健康的半仙采纳,获得10
4秒前
隐形曼青应助健康的半仙采纳,获得10
4秒前
搜集达人应助健康的半仙采纳,获得10
4秒前
深情安青应助健康的半仙采纳,获得10
4秒前
4秒前
Jasper应助健康的半仙采纳,获得10
4秒前
bkagyin应助健康的半仙采纳,获得10
4秒前
李健应助健康的半仙采纳,获得10
5秒前
科目三应助健康的半仙采纳,获得10
5秒前
汉堡包应助健康的半仙采纳,获得10
5秒前
SGOM完成签到 ,获得积分10
7秒前
赘婿应助哈哈哈采纳,获得10
8秒前
高熵合金发布了新的文献求助10
8秒前
11秒前
11秒前
李爱国应助健康的半仙采纳,获得10
11秒前
充电宝应助健康的半仙采纳,获得10
11秒前
酷波er应助健康的半仙采纳,获得10
11秒前
乐乐应助健康的半仙采纳,获得10
11秒前
科研通AI2S应助健康的半仙采纳,获得10
11秒前
星辰大海应助健康的半仙采纳,获得10
11秒前
共享精神应助健康的半仙采纳,获得10
11秒前
田様应助健康的半仙采纳,获得10
11秒前
领导范儿应助健康的半仙采纳,获得10
11秒前
坚强的灯泡完成签到,获得积分10
14秒前
16秒前
18秒前
20秒前
20秒前
乌冬面123发布了新的文献求助30
23秒前
fsznc完成签到 ,获得积分0
24秒前
玛卡巴卡完成签到 ,获得积分10
26秒前
LucienS发布了新的文献求助10
27秒前
今后应助prrrratt采纳,获得10
29秒前
燚槿完成签到 ,获得积分10
31秒前
田様应助笨笨桐采纳,获得10
31秒前
31秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 临床微生物学程序手册,多卷,第5版 2000
List of 1,091 Public Pension Profiles by Region 1621
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] | NHBS Field Guides & Natural History 1500
The Victim–Offender Overlap During the Global Pandemic: A Comparative Study Across Western and Non-Western Countries 1000
King Tyrant 720
T/CIET 1631—2025《构网型柔性直流输电技术应用指南》 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5590129
求助须知:如何正确求助?哪些是违规求助? 4674579
关于积分的说明 14794548
捐赠科研通 4630299
什么是DOI,文献DOI怎么找? 2532556
邀请新用户注册赠送积分活动 1501218
关于科研通互助平台的介绍 1468571